Eli Lilly reports slight uptick in revenue during second quarter

Eli Lilly (LLY) reported a 1% uptick in revenue during the second quarter.

The pharmaceutical giant said the slight revenue bump was due to greater sales of such medications as the diabetes drug Trulicity and the chemotherapy medication Cyramza, as well as revenue from Novartis Animal Health, which the company bought for $5.4 billion last year.

But the company says revenue might have been higher if not for poor foreign currency exchange rates, and the patent expiration of popular medicines like Cymbalta.

Earnings per share between April and June were 56 cents, or 90 cents per share not counting special items.

The company revised its earnings per share guidance for this year to between $2.20 to $2.30 and $3.20 to $3.30 not counting special items.

Shares were up 1.83% to $87.96 in pre-market trading following the earnings announcement.